Tamsulosin Hydrochloride
Product Images NDC 68071-2859

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 68071-2859). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2859 1)

Label for Tamsulosin Hydrochloride 0.4 mg capsules by NuCare Pharmaceuticals, Inc. The package contains 100 capsules. The label displays NDC 68071-2859-1, manufacturer details including Halo Pharmaceutical Industries Ltd. in India, and storage instructions to keep at controlled temperature 68-77°F. It includes warnings to keep out of reach of children and advises consulting the manufacturer’s label for a full ingredient list.*

FDA Label Image

Figure-1 (Tamsulosin Fig1)

A line graph displaying plasma concentration (ng/mL) over time (hours) comparing the pharmacokinetics of Tamsulosin Hydrochloride in fasted versus fed states. The graph shows plasma concentration peaking earlier and higher in the fasted state, with curves for both conditions declining over a 36-hour period.*

FDA Label Image

Figure-2a (Tamsulosin Fig2a)

A line graph showing mean change over duration of treatment in weeks for three groups: 0.8 mg dose, 0.4 mg dose, and placebo. The x-axis represents treatment duration from baseline to 13 weeks plus LOCF, and the y-axis represents mean change, with values ranging from 0 to -11. Data points show decreasing mean change for the treatment groups compared to placebo over time.*

FDA Label Image

Figure-2b (Tamsulosin Fig2b)

Line graph depicting mean change over the duration of treatment in weeks for Tamsulosin Hydrochloride at doses of 0.8 mg and 0.4 mg compared to placebo. The x-axis shows treatment duration from 0 to 13 weeks, while the y-axis represents mean change, with separate lines for each treatment group indicated by different markers (circles, triangles, squares). Sample sizes per time point are noted below the x-axis.*

FDA Label Image

Tamsulosin-fig3a (Tamsulosin Fig3a)

A line graph showing mean change in mL/sec over the duration of treatment in weeks. The graph compares three treatments: 0.8 mg, 0.4 mg, and placebo. Data points and trends are plotted for each treatment group from baseline through 13 weeks and at a LOCF (last observation carried forward) point, with sample sizes indicated below the x-axis.*

FDA Label Image

Tamsulosin-fig3b (Tamsulosin Fig3b)

A line graph depicting mean change in flow rate (mL/sec) over treatment duration in weeks. Three treatment groups are shown: Tamsulosin Hydrochloride 0.8 mg and 0.4 mg doses, and a placebo group. The 0.8 mg group shows the highest mean change throughout, followed by the 0.4 mg group, with placebo showing the lowest changes. Sample sizes at each time point are indicated below the x-axis.*

FDA Label Image

Chemical-structure (Tamsulosin Str)

Chemical structure diagram of Tamsulosin Hydrochloride, showing its molecular composition with labeled chemical groups including H2NO2S, CH3O, C2H5O, and associated hydrochloride (HCl) component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.